id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-317075-zegearxa	Madenidou, Anastasia-Vasiliki	Real-life experience of tocilizumab use in COVID-19 patients	2020-06-17		.txt	text/plain	883	59	47	The results are encouraging (75% improved, remained stable or with moderate disease with Tocilizumab), but should be evaluated with caution due to the low quality of studies (retrospective nature, small sample size, missing data, no clear outcome measures). According to the press release, a significantly lower proportion of patients reached the primary outcome (need for ventilation or The mean hospitalization time was 13.5 days after the treatment death at day 14) in the tocilizumab arm. Effective treatment of severe COVID-19 patients with tocilizumab Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab Case study: a patient with asthma, Covid-19 pneumonia and cytokine release syndrome treated with corticosteroids and tocilizumab First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab	./cache/cord-317075-zegearxa.txt	./txt/cord-317075-zegearxa.txt